Prostacyclin and its agonist (iloprost) are first-line treatments for patients with PAH, significantly decreasing ANP [33] and significantly increasing cardiac output [5,8,12], which is associated with improved survival [13]. The gene discussed is NPPA; the disease is pulmonary arterial hypertension.